MX375889B - Agente ligante de la il-17a y usos del mismo. - Google Patents

Agente ligante de la il-17a y usos del mismo.

Info

Publication number
MX375889B
MX375889B MX2016006101A MX2016006101A MX375889B MX 375889 B MX375889 B MX 375889B MX 2016006101 A MX2016006101 A MX 2016006101A MX 2016006101 A MX2016006101 A MX 2016006101A MX 375889 B MX375889 B MX 375889B
Authority
MX
Mexico
Prior art keywords
binding agent
antibody
psoriasis
interleukin
combined
Prior art date
Application number
MX2016006101A
Other languages
English (en)
Other versions
MX2016006101A (es
Inventor
Guoqing Cao
Jiajian Liu
Lianshan Zhang
Piaoyang Sun
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MX2016006101A publication Critical patent/MX2016006101A/es
Publication of MX375889B publication Critical patent/MX375889B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a un anticuerpo capaz de reconocer especialmente la IL-17A y de estar combinado con la IL-17A. El anticuerpo se puede utilizar para el tratamiento de inflamaciones y enfermedades autoinmunes causadas por la expresión alta de la interleucina-17A, tal como psoriasis, artritis psoriásica, espondilitis anquilosante, esclerosis múltiple y artritis inflamatoria.
MX2016006101A 2013-11-18 2014-10-27 Agente ligante de la il-17a y usos del mismo. MX375889B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310580942 2013-11-18
PCT/CN2014/089542 WO2015070697A1 (zh) 2013-11-18 2014-10-27 Il-17a结合物及其用途

Publications (2)

Publication Number Publication Date
MX2016006101A MX2016006101A (es) 2016-07-21
MX375889B true MX375889B (es) 2025-03-06

Family

ID=53056748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006101A MX375889B (es) 2013-11-18 2014-10-27 Agente ligante de la il-17a y usos del mismo.

Country Status (20)

Country Link
US (1) US9862765B2 (es)
EP (2) EP3670533A1 (es)
JP (1) JP6513657B2 (es)
KR (1) KR102278487B1 (es)
CN (1) CN104936981B (es)
AU (1) AU2014350758B2 (es)
CA (1) CA2929662C (es)
CY (1) CY1123493T1 (es)
ES (1) ES2818074T3 (es)
HR (1) HRP20201432T1 (es)
HU (1) HUE052184T2 (es)
LT (1) LT3072905T (es)
MX (1) MX375889B (es)
PL (1) PL3072905T3 (es)
PT (1) PT3072905T (es)
RS (1) RS61034B1 (es)
RU (1) RU2682046C1 (es)
SI (1) SI3072905T1 (es)
TW (1) TWI674273B (es)
WO (1) WO2015070697A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业(上海)股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
CN106474470B (zh) * 2015-08-28 2020-05-22 江苏恒瑞医药股份有限公司 一种抗il-17a抗体的组合物
CN107236041B (zh) * 2016-03-29 2020-07-24 舒泰神(北京)生物制药股份有限公司 Il-17抗体
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业(上海)股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
TN2019000082A1 (en) * 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
CN108359011B (zh) * 2017-07-21 2019-06-25 华博生物医药技术(上海)有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN107522783B (zh) * 2017-09-30 2020-07-07 华博生物医药技术(上海)有限公司 一种抗白介素17a的抗体、其制备方法和应用
KR102048475B1 (ko) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト TNFα及びIL-17Aに対する特異性を有する多重特異性抗体、IL-17Aを標的とする抗体、及びそれらの使用方法
WO2021018191A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
TW202241505A (zh) * 2021-01-04 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
CN115703841A (zh) * 2021-08-10 2023-02-17 复旦大学 白介素17a抗体与白介素22细胞因子融合蛋白及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
NZ574804A (en) * 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
AU2007352412B2 (en) * 2007-04-27 2013-05-16 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
EP2170958A1 (en) * 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
BRPI0908312A2 (pt) * 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
CA2737636A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
WO2011053763A2 (en) * 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
PH12013501435B1 (en) * 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
UY34410A (es) * 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf

Also Published As

Publication number Publication date
KR20160085793A (ko) 2016-07-18
CY1123493T1 (el) 2022-03-24
CN104936981B (zh) 2018-02-27
LT3072905T (lt) 2020-12-10
JP2017502924A (ja) 2017-01-26
RU2682046C1 (ru) 2019-03-14
EP3072905A4 (en) 2017-06-28
TW201520228A (zh) 2015-06-01
EP3670533A1 (en) 2020-06-24
US20160289321A1 (en) 2016-10-06
SI3072905T1 (sl) 2020-12-31
RS61034B1 (sr) 2020-12-31
AU2014350758B2 (en) 2019-07-25
CN104936981A (zh) 2015-09-23
RU2016122340A (ru) 2017-12-26
HK1212993A1 (zh) 2016-06-24
TWI674273B (zh) 2019-10-11
MX2016006101A (es) 2016-07-21
HUE052184T2 (hu) 2021-12-28
AU2014350758A1 (en) 2016-06-30
BR112016009948A2 (pt) 2017-12-05
US9862765B2 (en) 2018-01-09
KR102278487B1 (ko) 2021-07-19
EP3072905A1 (en) 2016-09-28
ES2818074T3 (es) 2021-04-09
JP6513657B2 (ja) 2019-05-15
CA2929662C (en) 2023-05-02
PT3072905T (pt) 2020-09-17
CA2929662A1 (en) 2015-05-21
EP3072905B1 (en) 2020-08-19
WO2015070697A1 (zh) 2015-05-21
PL3072905T3 (pl) 2021-03-08
HRP20201432T1 (hr) 2020-12-11

Similar Documents

Publication Publication Date Title
CY1123493T1 (el) Παραγων συνδεσης il-17a και χρησεις αυτου
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2015007034A (es) Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
JOP20140049B1 (ar) أجسام مضادة ترتبط بـ il-23
EA201791422A1 (ru) Фармацевтические продукты и устойчивые жидкие композиции антител к il-17
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
CR20160347A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
UY37779A (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
MX2015010427A (es) Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
MX2015010599A (es) Anticuerpos dirigidos contra il-33 y sus usos.
EA201792613A1 (ru) Модуляторы cot и способы их применения
CR20160333A (es) Proteinas de fusión de interleucina-2 y usos de las mismas
SG10201811017QA (en) Novel antibody frameworks
CL2016001592A1 (es) Anticuerpos y métodos de uso
MX2017010037A (es) Metodos de tratamiento de enfermedades inflamatorias.
WO2015106043A3 (en) Novel synthetic biology-based adcc technology
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
CO2018004493A2 (es) Métodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f)
MX392703B (es) Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.
MA41116B1 (fr) Compositions sélectives d'inhibiteur il-6-trans-signalisation
MX387187B (es) Inmunógenos fúngicos y materiales y métodos relacionados.
EA201691049A1 (ru) Энтомотоксичные полипептиды

Legal Events

Date Code Title Description
FG Grant or registration